Work

A Phase 2 Study of F-652, a Novel Tissue-Targeted Recombinant Human Interleukin-22 (IL-22) Dimer, for Treatment of Newly Diagnosed Acute Gvhd of the Lower GI Tract

Year: 2020

Type: article

Abstract: Background: IL-22 has been shown to support intestinal mucosa after damage through multiple mechanisms, including

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.bbmt.2019.12.124

Authors: Doris M. Ponce, Amin M. Alousi, Ryotaro Nakamura, Karamjeet S. Sandhu, Juliet N. Barker, Jinru Shia, Xiaoqiang Yan, William L. Daley, Gillian Moore, Samira Fatmi, Cristina Soto, Antonio Gomes, John Slingerland, Paul Giardina, Jonathan U. Peled, Marcel R.M. van den Brink, Alan M. Hanash

Institutions: Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, The University of Texas MD Anderson Cancer Center, University Medical Center Hamburg-Eppendorf, City Of Hope National Medical Center, The Ohio State University, Massachusetts General Hospital, Children's Hospital of Philadelphia, Evive Biotech (China), Hospital of the University of Pennsylvania, Abramson Cancer Center

Language: English

Topic: Hematopoietic Stem Cell Transplantation

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,650

Funders: Wayne State University, Ohio State University, School of Public Health, University of Michigan, Barbara Ann Karmanos Cancer Institute

OpenAlex ID: W3003067108

FWCI: 1.578

Cites:

Cited by: 13

Related to: 10